当然，新评分标准不仅对企业本身、而且对试图在“拉动”机制和目前的优先药物需求间达成平衡的决策者也非常重要。
And, of course, the new scoring will also be important to the companies themselves, and for policymakers who are trying to strike a balance between “pull” incentives and current priority-drug needs.